{
    "nctId": "NCT00102219",
    "briefTitle": "A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer",
    "officialTitle": "A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 77,
    "primaryOutcomeMeasure": "To assess the antitumor activity of pemetrexed plus doxorubicin, as measured by overall tumor response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of locally advanced or metastatic breast cancer that is not amenable to local treatment.\n* Patients must be chemo-naive or have received only neoadjuvant and/or adjuvant chemotherapy.\n* At least one measurable lesion.\n* No chemotherapy within 4 weeks prior to enrollment.\n* Signed informed consent from the patient.\n\nExclusion Criteria:\n\n* Prior chemotherapy for metastatic breast cancer.\n* Prior treatment with any anthracyclines or anthracenedione-containing regimen.\n* Treatment within the last 30 days with any drug that has not received regulatory approval.\n* Pregnancy and/or breast feeding.\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}